Neuroblastoma Clinical Trials
Here are the 6 most popular medical studies for neuroblastoma
CAR T-cell Therapy
CAR T-Cells for Neuroblastoma
This trial is testing a new cancer treatment that combines two existing ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. The new treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9
ALK Inhibitor
Lorlatinib + Topotecan + Cyclophosphamide + Filgrastim/pegfilgrastim for Neuroblastoma
This trial is testing a new drug, called lorlatinib, to see if it is safe and effective in children with relapsed or refractory neuroblastoma. This is a Phase I trial, which means that the goal is to find the best dose of the drug to give. The trial will first test the drug in a small group of patients to see if it is safe. If it is, then the trial will move on to testing different doses of the drug in a larger group of patients.
Cancer Vaccine
Tumor Cell Vaccination + Cytoxan for Neuroblastoma
This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.
Popular filter options for neuroblastoma trials
NBL Clinical Trials
View 94 NBL medical studies.
Radiation
External beam radiotherapy +1 More for Neuroblastoma
This trial aims to understand how radiation treats cancer while avoiding side effects, by collecting data & biospecimens before, during & after radiation & annotating them w/clinical, biological & other features.
CAR T-cell Therapy
B7-H3 CAR T-cell Therapy for Pediatric Patients with Solid Tumors
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
Solid Tumors Clinical Trials
View 29 Solid Tumors medical studies.
CAR T-cell Therapy
B7-H3 CAR T-cell Therapy for Pediatric Patients with Solid Tumors
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
Checkpoint Inhibitor
Dual Checkpoint Inhibition + Cryoablation for Pediatric Solid Tumors
“ We are looking for Clinical trial, Priyakshi already undergone VAC & VDC followed by Pazopanib and Everlomus. Currently under medication for TRAMETINIB.”
Topoisomerase I inhibitors
VAL-413 + Temozolomide for Pediatric Solid Tumors
This trial is testing a flavored, orally-administered form of irinotecan (VAL-413) given with temozolomide to see if it is safe and effective for treating recurrent pediatric solid tumors, including neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma.
Metastatic Neuroblastoma Clinical Trials
View 94 metastatic neuroblastoma medical studies.
CAR T-cell Therapy
Gamma Delta T Cells + Chemoimmunotherapy for Neuroblastoma
This trial is testing a new immunotherapy treatment for neuroblastoma that uses gamma delta T cells in combination with other drugs. The goal is to improve upon GD2 chemoimmunotherapy regimens for neuroblastoma by delivering standard drugs like temozolomide, irinotecan, and dinutuximab in combination with gamma delta T cells.
Monoclonal Antibodies
Immunotherapy with Expanded NK Cells for Neuroblastoma
This trial will determine how well autologous expanded natural killer cells work with standard dosing of dinutuximab and with or without lenalidomide in treating children with neuroblastoma that has come back or does not respond to treatment.
Immunotherapy
Haploidentical Transplantation + Zoledronate for Pediatric Hematologic Malignancies and Solid Tumors
This trial is testing a new way to transplant stem cells from a donor who is only a half-match to the patient, using a drug to remove TCRαβ+ cells and CD19+ cells.
Phase 3 Neuroblastoma Clinical Trials
View 94 phase 3 neuroblastoma medical studies.
Monoclonal Antibodies
131I-omburtamab Radioimmunotherapy for Neuroblastoma
This trial will test a new treatment for children with neuroblastoma that has spread to the brain or spinal cord. Up to 2 rounds of treatment will be given, and researchers will track how well the treatment works and how safe it is.
Retinoid
Isotretinoin +/- Dinutuximab, Aldesleukin, and Sargramostim for Neuroblastoma
This trial will compare isotretinoin alone to isotretinoin with dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating patients with neuroblastoma.
Neuroblastoma Clinical Trials With No Placebo
View 94 neuroblastoma medical studies that do not have a placebo group.
Radiation
External beam radiotherapy +1 More for Neuroblastoma
This trial aims to understand how radiation treats cancer while avoiding side effects, by collecting data & biospecimens before, during & after radiation & annotating them w/clinical, biological & other features.
CAR T-cell Therapy
B7-H3 CAR T-cell Therapy for Pediatric Patients with Solid Tumors
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
View More Neuroblastoma Trials
See another 62 many medical studies focused on neuroblastoma.
Frequently Asked Questions
Introduction to neuroblastoma
What are the top hospitals conducting neuroblastoma research?
When it comes to the fight against neuroblastoma, a rare and aggressive cancer that primarily affects children, several top hospitals across the United States are leading the charge in clinical trials. In Los Angeles, Children's Hospital Los Angeles takes center stage with an impressive 28 ongoing trials focused on neuroblastoma. This renowned institution has been at the forefront of research for this condition since recording its first trial in 1988. Similarly, Cincinnati Children's Hospital Medical Center also boasts 28 active neuroblastoma trials and carries an exceptional track record with a total of 86 completed studies since their first recorded trial in 1988.
Not to be outdone, Memorial Sloan Kettering Cancer Center in New York is making significant contributions as well. With 28 currently active neuroblastoma trials and a solid history of 55 previous studies conducted since initiating their inaugural trial in 1995, they remain dedicated to advancing our understanding and treatment options for this challenging disease.
Meanwhile, Children's Hospital Colorado located in Aurora has emerged as another key player with its commitment to finding innovative solutions through its ongoing participation in twenty-five active neuroblastoma trials while having conducted forty-seven overall studies starting from their initial investigation into these cases back in2000.With consistent pursuit towards medical progress within Kansas City area itself;Children’s Mercy Hospitals & Clinics have not only made valuable contribution by actively partaking25ongoing research projects specifically targeting Neuroblatstomatic conditions but also deserve appreciation for dedicating time to previous four decades long forty investigations covering numerous aspects pertaining such complex ailment ,starting from year2000 onwards
These esteemed hospitals represent hope for families affected by neuroblastoma and exemplify the tireless efforts undertaken by healthcare professionals nationwide. The collective endeavors of these institutions bring us closer to breakthroughs that will improve outcomes for patients battling this devastating disease. Through cutting-edge research and compassionate care, they champion advancements that hold promise for a brighter future in the fight against neuroblastoma.
Which are the best cities for neuroblastoma clinical trials?
When it comes to neuroblastoma clinical trials, several cities have emerged as key hubs for research and innovation. New York City leads the pack with 72 active trials, focusing on a range of treatments including Palbociclib, Selumetinib Sulfate, and others. Following closely behind are Saint Louis in Missouri with 64 ongoing studies exploring options like Palbociclib and Cyclophosphamide, and Orlando in Florida with 61 trials investigating similar interventions. Chicago in Illinois also boasts a significant presence with 53 active trials studying Temozolomide and Autologous Hematopoietic Stem Cell Transplantation among other potential therapies. Finally, Boston in Massachusetts. New York City leads the pack with 72 active trials, focusing on a range of treatments including Palbociclib, Selumetinib Sulfate, and others. Following closely behind are Saint Louis in Missouri with 64 ongoing studies exploring options like Palbociclib and Cyclophosphamide, and Orlando in Florida with 61 trials investigating similar interventions. Chicago in Illinois also boasts a significant presence with 53 active trials studying Temozolomide and Autologous Hematopoietic Stem Cell Transplantation among other potential therapies. Finally, Boston in Massachusetts rounds out the top five cities with 48 ongoing studies investigating treatments such as induction therapy, consolidation therapy, ASCT (autologous stem cell transplantation), and more. These cities offer individuals battling neuroblastoma access to cutting-edge clinical trials that give hope for improved outcomes through innovative approaches to treatment.
Which are the top treatments for neuroblastoma being explored in clinical trials?
Cutting-edge research in the fight against neuroblastoma has identified several promising treatments currently under exploration in clinical trials. Leading the pack is a pharmacological study, with four active trials and 16 all-time neuroblastoma trials since its initial listing in 2001. DFMO, another notable contender, shines brightly with three ongoing trials and six all-time neuroblastoma studies since its introduction in 2010. Also showing great potential is 131I-MIBG, which joins the race boasting two active and five all-time neuroblastoma trials following its first appearance on the scene in 2005. Rounding out this impressive lineup is nivolumab, gaining traction with two active and six all-time neuroblastoma trials after making waves upon its arrival in 2015. With each trial comes renewed hope for finding effective treatments for those facing this challenging disease.
What are the most recent clinical trials for neuroblastoma?
Recent clinical trials offer promising prospects for the treatment of neuroblastoma, a challenging pediatric cancerf neuroblastoma, a challenging pediatric cancer. One notable trial investigates the combination of ex vivo expanded allogeneic γδ T cells with dinutuximab, temozolomide, irinotecan, and zoledronate. In another study, researchers are exploring an innovative approach using anti-CD30 bispecific antibody-armed anti-CD3-activated autologous T-cells (CD30 biAb-AATC). These trials aim to evaluate their effectiveness in improving outcomes for patients with neuroblastoma. While still in early phases, these advancements hold great potential for enhancing therapeutic options and ultimately improving survival rates for those battling this aggressive disease.
What neuroblastoma clinical trials were recently completed?
A recent completion of a clinical trial for neuroblastoma involved the investigation of chemotherapy and was sponsored by AbbVie. This trial concluded in November 2017, providing valuable insights into the efficacy and safety of this treatment approach. The findings from this study contribute to our understanding of how chemotherapy can be utilized in combating neuroblastoma, offering potential avenues for improved patient outcomes.